MEDICAL MARIJUANA RESEARCH NEWSLETTER



SUMMER 2023


WELCOME TO MEDICAMENT,

the Consortium for Medical Marijuana Clinical Outcomes Research's quarterly newsletter.

The Consortium, founded by the State of Florida, conducts, disseminates, and supports research on the use and effects of medical marijuana on patient outcomes.

In the Summer 2023 issue of MEDICAMENT:

- Event Summary: CCORC 2023
- Clinical Core Updates Medi-
- cal Marijuana and Me (M³)
- Outreach Updates
- Get Involved in Research



To learn more about the Consortium and our programs, visit us at mmjoutcomes.org.

CANNABIS CLINICAL OUTCOMES RESEARCH CONFERENCE (CCORC) HOSTS THIRD ANNUAL MEETING IN ORLANDO

CCORC 2023 boasts significant expansion of scientific program



On Thursday, May 18th and Friday, May 19th, 2023, the Consortium for Medical Marijuana Clinical Outcomes Research hosted its third annual research conference, Cannabis Clinical Outcomes Research Conference (CCORC). The conference was held in person, and with virtual options, at the UF Research and Academic Center at Lake Nona, Orlando, FL.

CCORC connects researchers, physicians, community stakeholders, and industry representatives to disseminate research, foster thoughtful discussion, and encourage collaboration in medical cannabis research. CCORC 2023's program included three keynote speakers, panel discussions, two poster sessions for abstracts selected following peer review, and eight oral presentations of top abstracts. This year saw a near-doubling of accepted abstracts, totaling in 55, compared to 32 last year. Participation from students also rose from 17% of attendees in 2022 to 34% of attendees for 2023.

CCORC 2023 Summary Cont'd

Three main themes on clinical cannabis research conduct and interpretation emerged throughout the conference:



- Disentangling conflicting evidence in research studying the relationship between medical cannabis and public health
- Seeking solutions to address barriers faced when conducting clinical cannabis research – especially with use in special populations
- 3. Unpacking the data behind cannabis use and metal health outcomes

Registrants were able to earn Continuing Medical Education (CME) or Continuing Pharmacy Education (CPE) credits for attending components of the scientific program.

Abstracts presented at CCORC 2023 will be published in *Medical Cannabis and Cannabinoids*, the official journal of the Consortium for Medical Marijuana Clinical Outcomes Research.

All CCORC 2023 attendees (both in-person and virtual) have access to recordings of all three keynote presentations as well as the event's opening and closing remarks and awards ceremony. If you are a CCORC 2023 attendee and wish to access these recordings, please contact <u>mmj.outcomes@cop.ufl.</u> edu

CCORC 2023 Awardees

Each year, CCORC concludes with an awards ceremony recognizing outstanding contributors to the conference's scientific program. The following awardees received recognition at CCORC 2023.

Top Scoring Student Abstracts

Savoya Joyner Florida State University Isabella Jimenez University of Miami Alexandria Senetra University of Florida

Top Scoring Non-Student Abstracts

Chandrakala Narasimhulu University of Central Florida Simone Marini University of Florida Karina Villalba Florida Atlantic University

Best Poster Presentation

Phillip Melchert University of Florida

The fourth annual CCORC is planned for summer 2024, official date TBA.

Visit the links below for more information regarding CCORC 2023: <u>View Photo Gallery ></u> <u>View Full Conference Program ></u> <u>View Digital Archive of Abstracts and Posters ></u>



CCORC 2023 Keynote Speakers



Jodi Gilman, PhD

Director of Neuroscience, Center for Addiction Medicine, Massachusetts General Hospital *Associate Professor*, Dept. of Psychiatry, Harvard Medical School

Recreational and Medical Cannabis: Potential Implications on Cognition and Clinical Outcomes



Kelly Young-Wolff, PhD, MPH

Adjunct Associate Professor, Dept. of Psychiatry, UC San Francisco Consulting Assistant Professor, School of Medicine, Stanford University Associate Professor and Clinical Psychologist and Research Scientist, Kaiser Permanente

Cannabis Use During Pregnancy: Research from Policy to Practice



Shanna Babalonis, PhD

Director, Cannabis Center, University of Kentucky *Assistant Professor,* Dept. of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky

Opioid and Cannabinoid Interactions: Abuse Potential and Clinical Implications

CCORC 2023 Oral Presenters of Top Abstracts



Mounika Aare, MS

Graduate Scholar, Florida State University In-vitro Evaluation Of Cannabinoids In Combination with Terpenes In Overcoming Cancer Resistance



Bassma Eltanameli, BPharm, MSc PhD Student, University of Florida Predicting the potential for cannabinoids-drug interactions with major CYP450 using model-based approaches



Kristin Perrucci

Research Associate, University of Miami **Evaluation of cannabis constituents in preventing or reversing phantom limb pain in rats**



Sabrina Zequeira, MS Graduate Student, University of Florida Chronic oral administration of delta-9-tetrahydrocannabinol (THC) enhances working memory in aged but not young rats



Martina Compagno

PhD Student, Florida State University **Health and Behavioral Consequences of Perinatal Cannabidiol Exposure in Mice Raised to Adult**

Simone Marini, PhD

Assistant Professor, University of Florida An anti-inflammatory gene expression signature is associated with CBD treatment in people living with HIV

Ruba Sajdeya, MD



PhD Candidate, University of Florida A novel natural language processing algorithm to unlock preoperative cannabis use status data from unstructured narrative clinical notes

Isabella Jimenez Undergraduate Resear

Undergraduate Research Assistant, University of Miami

Pain Severity Changes among Cannabis Consumers before and after Ketamine-Assisted Psychotherapy: Results from a Pilot Study Comparing Psycholytic and Psychedelic Approaches

CLINICAL CORE UPDATES

M³ Longitudinal and Cross-Sectional Patient Recruitment Now Complete, Cross-Sectional Study Data Access Available to Researchers

The Medical Marijuana and Me (M³) team has completed patient recruitment for both its crosssectional and longitudinal studies.

Data from the M³ cross-sectional study are now available for interested researchers. The data summarize information on utilization pattern and health outcomes from 632 current MMJ users and are available for researchers addressing questions within the following suggested domain and others:

- Comorbidities
- Concurrent Medication Use
- Concurrent Substance Use
- Demographic Characteristics of the Study Participants
- MMJ Products and Use Patterns
- MMJ-Related Side Effects
- Perceived Effects on Physical and Mental Health
- Reasons for Using MMJ

The Data Access Request Application is now open for submissions. More information, and a summary of research that has already been proposed, are available at <u>mmjoutcomes.org/m3study</u>.

If you have questions or would like to speak to a study team member, you may call/text (352) 658-3735 or email m3cohort@phhp.ufl.edu.

Cross-Sectional Data Snapshot: Top 10 Self-Reported Health Diagnoses

Health Condition	Percent
Anxiety	71%
Depression	62%
Chronic Pain	49%
Insomnia/Sleeping Problems	47%
Post-Traumatic Stress Disorder (PTSD)	43%
Headaches/Migraines	34%
High Blood Pressure	26%
Attention-Deficit/Hyperactive Disorder (ADHD)	19%
Bipolar Disorder	14%
Fibromyalgia	13%


OUTREACH UPDATES

Consortium Members Participate in Conferences Across the Country

On May 31, Consortium Associate Director, Dr. Robert Cook, particpated in a pre-conference workshop panel for the Florida Medical Cannabis Conference and Exhibition in Orlando, FL. This panel, entitled "Cannabis – From Marijuana to Hemp," featured Jeffrey Block, MD as moderator and co-panelists Zachary Brym, PhD and Christopher McCurdy, Phd discussing the emerging challenges in conducting research related to marijuana and hemp in Florida.

In June, Dr. Cook, along with predoctoral trainee Juan Perez, presented research from the M³ study at the annual meeting for the College on Problems of Drug Dependence in Denver, CO. Dr. Cook presented findings associated with risk for cannabis use disorder among adults using medical marijuana in Florida, and Perez presented findings related to the use of medical marijuana for sleep.

The team will also present findings from the M³ study at the annual meeting of the Research Society on Marijuana, to be held in Long Beach, CA, in late-July 2023. These presentations will include some initial results related to the use of medical marijuana for anxiety, sleep, and pain.



Pictured Here:

M³Research Assistant, Kendal Robinson, presents a poster based on M³ study findings at the Society for Epidemiologic Research's annual meeting in Portland, OR.

GET INVOLVED IN RESEARCH

CARMMA: Changing the way we collaborate across the state of Florida

The <u>Connect and Advance Research for Medical Marijuana Analysis (CARMMA) Database</u> is accessible to researchers, physicians, and industry collaborators.

We believe collaborations bring research advancements. The CARMMA Database connects researchers, clinicians, and industry to foster medical marijuana research.

Anyone interested in engaging in medical marijuana research is invited to register in CARMMA to find collaborators.

JOIN THE CARMMA DATABASE



Have news or feedback to share? Let us know!

Share your Consortium-related research and news through our <u>submission form</u>.

Share your comments on our newsletter through our <u>feedback form</u>.

Don't want to miss any MEDICAMENT issues?

Share your contact information through our <u>newsletter sign-up form</u>.

Read previous MEDICAMENT issues on our website.



Consortium for Medical Marijuana Clinical Outcomes Research

6 MEDICAMENT: MEDICAI Marijuana rEsearch NewsleTter